StreetInsider.com News Articles

Predictmedix AI to Present at the 25th MK Investment Conference in Munich, Germany

Mon, 29 Sep 2025 07:00:00 -0500

TORONTO--(BUSINESS WIRE)-- Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0) (“Predictmedix” or the “Company”), an emerging leader in AI-powered health and safety technology, is pleased to announce that its Chief Operating Officer and Co-founder, Dr. Rahul Kushwah, will be presenting at the prestigious 25th MK Investment Conference in Munich, Germany, on October 1, 2025.

The MK Investment Conference, hosted by Michael Kott and CM-Equity AG, is one of Europe’s most anticipated investment gatherings. A large and diverse investor audience is expected to attend, with strong interest in AI, Longevity, Tech, and ESG sectors. The event serves as

Predictmedix AI to Present at the 25th MK Investment Conference in Munich, Germany

Mon, 29 Sep 2025 07:00:00 -0500

Predictmedix AI to Present at the 25th MK Investment Conference in Munich, Germany

Mon, 29 Sep 2025 07:00:00 -0500

Predictmedix AI to Present at the 25th MK Investment Conference in Munich, Germany

Mon, 29 Sep 2025 07:00:00 -0500

Predictmedix AI to Present at the 25th MK Investment Conference in Munich, Germany

Mon, 29 Sep 2025 07:00:00 -0500

Predictmedix AI to Present at the 25th MK Investment Conference in Munich, Germany

Mon, 29 Sep 2025 07:00:00 -0500

Predictmedix AI to Present at the 25th MK Investment Conference in Munich, Germany

Mon, 29 Sep 2025 07:00:00 -0500

Predictmedix AI to Present at the 25th MK Investment Conference in Munich, Germany

Mon, 29 Sep 2025 07:00:00 -0500

Predictmedix AI Announces Multi-Vertical Growth Strategy to Become an AI Health-Technology Leader

Wed, 24 Sep 2025 07:00:00 -0500

Clinically validated SmartHealth AI Stations anchor expansion into Clinical-Trial Optimization and Consumer Digital Health, creating multiple recurring-revenue opportunities

TORONTO--(BUSINESS WIRE)-- Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0) (“Predictmedix” or the “Company”), an emerging leader in AI-powered health and safety technology, today outlined a strategic plan to evolve from a single-product health-screening company into a diversified, AI-driven health-technology enterprise with three complementary growth platforms.

Three Growth Platforms

Clinical-Trial AI Platform – Primary Near-Term Driver

Predictmedix is developing an adaptive-AI engine designed to simulate, optimize, and predict outcomes across multi-site clinical trials—addressing a global clinical trials market projected to reach USD

Predictmedix AI Announces Multi-Vertical Growth Strategy to Become an AI Health-Technology Leader

Wed, 24 Sep 2025 07:00:00 -0500

Clinically validated SmartHealth AI Stations anchor expansion into Clinical-Trial Optimization and Consumer Digital Health, creating multiple recurring-revenue opportunities

TORONTO--(BUSINESS WIRE)-- Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0) (“Predictmedix” or the “Company”), an emerging leader in AI-powered health and safety technology, today outlined a strategic plan to evolve from a single-product health-screening company into a diversified, AI-driven health-technology enterprise with three complementary growth platforms.

Three Growth Platforms

Clinical-Trial AI Platform – Primary Near-Term Driver

Predictmedix AI Announces Multi-Vertical Growth Strategy to Become an AI Health-Technology Leader

Wed, 24 Sep 2025 07:00:00 -0500

Clinically validated SmartHealth AI Stations anchor expansion into Clinical-Trial Optimization and Consumer Digital Health, creating multiple recurring-revenue opportunities

TORONTO--(BUSINESS WIRE)-- Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0) (“Predictmedix” or the “Company”), an emerging leader in AI-powered health and safety technology, today outlined a strategic plan to evolve from a single-product health-screening company into a diversified, AI-driven health-technology enterprise with three complementary growth platforms.

Three Growth Platforms

Clinical-Trial AI Platform – Primary Near-Term Driver

Predictmedix AI Announces Multi-Vertical Growth Strategy to Become an AI Health-Technology Leader

Wed, 24 Sep 2025 07:00:00 -0500

Clinically validated SmartHealth AI Stations anchor expansion into Clinical-Trial Optimization and Consumer Digital Health, creating multiple recurring-revenue opportunities

TORONTO--(BUSINESS WIRE)-- Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0) (“Predictmedix” or the “Company”), an emerging leader in AI-powered health and safety technology, today outlined a strategic plan to evolve from a single-product health-screening company into a diversified, AI-driven health-technology enterprise with three complementary growth platforms.

Three Growth Platforms

Clinical-Trial AI Platform – Primary Near-Term Driver

Predictmedix AI Announces Multi-Vertical Growth Strategy to Become an AI Health-Technology Leader

Wed, 24 Sep 2025 07:00:00 -0500

Clinically validated SmartHealth AI Stations anchor expansion into Clinical-Trial Optimization and Consumer Digital Health, creating multiple recurring-revenue opportunities

TORONTO--(BUSINESS WIRE)-- Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0) (“Predictmedix” or the “Company”), an emerging leader in AI-powered health and safety technology, today outlined a strategic plan to evolve from a single-product health-screening company into a diversified, AI-driven health-technology enterprise with three complementary growth platforms.

Three Growth Platforms

Clinical-Trial AI Platform – Primary Near-Term Driver

Predictmedix AI Announces Multi-Vertical Growth Strategy to Become an AI Health-Technology Leader

Wed, 24 Sep 2025 07:00:00 -0500

Clinically validated SmartHealth AI Stations anchor expansion into Clinical-Trial Optimization and Consumer Digital Health, creating multiple recurring-revenue opportunities

TORONTO--(BUSINESS WIRE)-- Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0) (“Predictmedix” or the “Company”), an emerging leader in AI-powered health and safety technology, today outlined a strategic plan to evolve from a single-product health-screening company into a diversified, AI-driven health-technology enterprise with three complementary growth platforms.

Three Growth Platforms

Clinical-Trial AI Platform – Primary Near-Term Driver

Predictmedix AI Announces Multi-Vertical Growth Strategy to Become an AI Health-Technology Leader

Wed, 24 Sep 2025 07:00:00 -0500

Clinically validated SmartHealth AI Stations anchor expansion into Clinical-Trial Optimization and Consumer Digital Health, creating multiple recurring-revenue opportunities

TORONTO--(BUSINESS WIRE)-- Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0) (“Predictmedix” or the “Company”), an emerging leader in AI-powered health and safety technology, today outlined a strategic plan to evolve from a single-product health-screening company into a diversified, AI-driven health-technology enterprise with three complementary growth platforms.

Three Growth Platforms

Clinical-Trial AI Platform – Primary Near-Term Driver

Predictmedix AI Announces Multi-Vertical Growth Strategy to Become an AI Health-Technology Leader

Wed, 24 Sep 2025 07:00:00 -0500

Clinically validated SmartHealth AI Stations anchor expansion into Clinical-Trial Optimization and Consumer Digital Health, creating multiple recurring-revenue opportunities

TORONTO--(BUSINESS WIRE)-- Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0) (“Predictmedix” or the “Company”), an emerging leader in AI-powered health and safety technology, today outlined a strategic plan to evolve from a single-product health-screening company into a diversified, AI-driven health-technology enterprise with three complementary growth platforms.

Three Growth Platforms

Clinical-Trial AI Platform – Primary Near-Term Driver

Predictmedix AI Announces Multi-Vertical Growth Strategy to Become an AI Health-Technology Leader

Wed, 24 Sep 2025 07:00:00 -0500

Clinically validated SmartHealth AI Stations anchor expansion into Clinical-Trial Optimization and Consumer Digital Health, creating multiple recurring-revenue opportunities

TORONTO--(BUSINESS WIRE)-- Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0) (“Predictmedix” or the “Company”), an emerging leader in AI-powered health and safety technology, today outlined a strategic plan to evolve from a single-product health-screening company into a diversified, AI-driven health-technology enterprise with three complementary growth platforms.

Three Growth Platforms

Clinical-Trial AI Platform – Primary Near-Term Driver

Predictmedix AI Announces Multi-Vertical Growth Strategy to Become an AI Health-Technology Leader

Wed, 24 Sep 2025 07:00:00 -0500

Clinically validated SmartHealth AI Stations anchor expansion into Clinical-Trial Optimization and Consumer Digital Health, creating multiple recurring-revenue opportunities

TORONTO--(BUSINESS WIRE)-- Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0) (“Predictmedix” or the “Company”), an emerging leader in AI-powered health and safety technology, today outlined a strategic plan to evolve from a single-product health-screening company into a diversified, AI-driven health-technology enterprise with three complementary growth platforms.

Three Growth Platforms

Clinical-Trial AI Platform – Primary Near-Term Driver

Predictmedix AI Announces Multi-Vertical Growth Strategy to Become an AI Health-Technology Leader

Wed, 24 Sep 2025 07:00:00 -0500

Clinically validated SmartHealth AI Stations anchor expansion into Clinical-Trial Optimization and Consumer Digital Health, creating multiple recurring-revenue opportunities

TORONTO--(BUSINESS WIRE)-- Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0) (“Predictmedix” or the “Company”), an emerging leader in AI-powered health and safety technology, today outlined a strategic plan to evolve from a single-product health-screening company into a diversified, AI-driven health-technology enterprise with three complementary growth platforms.

Three Growth Platforms

Clinical-Trial AI Platform – Primary Near-Term Driver

Predictmedix AI Announces Multi-Vertical Growth Strategy to Become an AI Health-Technology Leader

Wed, 24 Sep 2025 07:00:00 -0500

Clinically validated SmartHealth AI Stations anchor expansion into Clinical-Trial Optimization and Consumer Digital Health, creating multiple recurring-revenue opportunities

TORONTO--(BUSINESS WIRE)-- Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0) (“Predictmedix” or the “Company”), an emerging leader in AI-powered health and safety technology, today outlined a strategic plan to evolve from a single-product health-screening company into a diversified, AI-driven health-technology enterprise with three complementary growth platforms.

Three Growth Platforms

Clinical-Trial AI Platform – Primary Near-Term Driver

Predictmedix AI Expands into Mobile Diagnostics with New AI-Driven Diabetes Screening Platform

Wed, 02 Jul 2025 07:01:00 -0500

TORONTO--(BUSINESS WIRE)-- Predictmedix AI Inc. (CSE: PMED | OTC: PMEDF | FRA: 3QP), a leader in artificial intelligence-driven health screening solutions, is expanding into the direct-to-consumer market with a mobile solution designed to deliver rapid, non-invasive diabetic screening — with India identified as the initial launchpad for this transformative initiative. Leveraging the company’s proprietary AI technology, the platform is intended to empower millions with instant access to diabetic risk assessments using only a smartphone, eliminating the need for blood draws, lab visits, or clinical infrastructure.

By combining advanced facial and biometric analysis with seamless smartphone delivery, the solution

Predictmedix AI Expands into Mobile Diagnostics with New AI-Driven Diabetes Screening Platform

Wed, 02 Jul 2025 07:01:00 -0500

By combining advanced facial and biometric analysis with seamless smartphone delivery, the solution

Predictmedix AI Expands into Mobile Diagnostics with New AI-Driven Diabetes Screening Platform

Wed, 02 Jul 2025 07:01:00 -0500

By combining advanced facial and biometric analysis with seamless smartphone delivery, the solution

Predictmedix AI Expands into Mobile Diagnostics with New AI-Driven Diabetes Screening Platform

Wed, 02 Jul 2025 07:01:00 -0500

By combining advanced facial and biometric analysis with seamless smartphone delivery, the solution

Predictmedix AI Expands into Mobile Diagnostics with New AI-Driven Diabetes Screening Platform

Wed, 02 Jul 2025 07:01:00 -0500

By combining advanced facial and biometric analysis with seamless smartphone delivery, the solution